Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.83
SWTUY's Cash to Debt is ranked lower than
70% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. SWTUY: 0.83 )
Ranked among companies with meaningful Cash to Debt only.
SWTUY' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.74 Max: No Debt
Current: 0.83
Equity to Asset 0.70
SWTUY's Equity to Asset is ranked higher than
66% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. SWTUY: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
SWTUY' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.73 Max: 0.77
Current: 0.7
0.48
0.77
Interest Coverage No Debt
SWTUY's Interest Coverage is ranked higher than
79% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. SWTUY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SWTUY' s 10-Year Interest Coverage Range
Min: 0.79  Med: 5002.76 Max: 9999.99
Current: No Debt
0.79
9999.99
F-Score: 8
Z-Score: 9.74
M-Score: -2.04
WACC vs ROIC
8.26%
3.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.66
SWTUY's Operating margin (%) is ranked higher than
60% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. SWTUY: 4.66 )
Ranked among companies with meaningful Operating margin (%) only.
SWTUY' s 10-Year Operating margin (%) Range
Min: -33.86  Med: 1.26 Max: 31.83
Current: 4.66
-33.86
31.83
Net-margin (%) 5.76
SWTUY's Net-margin (%) is ranked higher than
71% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. SWTUY: 5.76 )
Ranked among companies with meaningful Net-margin (%) only.
SWTUY' s 10-Year Net-margin (%) Range
Min: -29.4  Med: 0.94 Max: 22.31
Current: 5.76
-29.4
22.31
ROE (%) 3.69
SWTUY's ROE (%) is ranked higher than
57% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.85 vs. SWTUY: 3.69 )
Ranked among companies with meaningful ROE (%) only.
SWTUY' s 10-Year ROE (%) Range
Min: -24.5  Med: 1.43 Max: 19.35
Current: 3.69
-24.5
19.35
ROA (%) 2.62
SWTUY's ROA (%) is ranked higher than
63% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. SWTUY: 2.62 )
Ranked among companies with meaningful ROA (%) only.
SWTUY' s 10-Year ROA (%) Range
Min: -14.82  Med: 0.74 Max: 16.94
Current: 2.62
-14.82
16.94
ROC (Joel Greenblatt) (%) 13.25
SWTUY's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. SWTUY: 13.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SWTUY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -59.86  Med: -7.45 Max: 13.31
Current: 13.25
-59.86
13.31
Revenue Growth (3Y)(%) 7.50
SWTUY's Revenue Growth (3Y)(%) is ranked higher than
59% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. SWTUY: 7.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SWTUY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -34.2  Med: -12.55 Max: 7.5
Current: 7.5
-34.2
7.5
» SWTUY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SWTUY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 171.30
SWTUY's P/E(ttm) is ranked lower than
97% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. SWTUY: 171.30 )
Ranked among companies with meaningful P/E(ttm) only.
SWTUY' s 10-Year P/E(ttm) Range
Min: 21.64  Med: 132.82 Max: 5660
Current: 171.3
21.64
5660
PE(NRI) 172.70
SWTUY's PE(NRI) is ranked lower than
96% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. SWTUY: 172.70 )
Ranked among companies with meaningful PE(NRI) only.
SWTUY' s 10-Year PE(NRI) Range
Min: 21.76  Med: 114.55 Max: 1830
Current: 172.7
21.76
1830
P/B 6.25
SWTUY's P/B is ranked lower than
76% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. SWTUY: 6.25 )
Ranked among companies with meaningful P/B only.
SWTUY' s 10-Year P/B Range
Min: 0.71  Med: 2.61 Max: 7.98
Current: 6.25
0.71
7.98
P/S 9.62
SWTUY's P/S is ranked lower than
80% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. SWTUY: 9.62 )
Ranked among companies with meaningful P/S only.
SWTUY' s 10-Year P/S Range
Min: 1.07  Med: 4.80 Max: 12.78
Current: 9.62
1.07
12.78
PFCF 402.96
SWTUY's PFCF is ranked lower than
98% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.01 vs. SWTUY: 402.96 )
Ranked among companies with meaningful PFCF only.
SWTUY' s 10-Year PFCF Range
Min: 12.61  Med: 111.29 Max: 671.43
Current: 402.96
12.61
671.43
POCF 108.80
SWTUY's POCF is ranked lower than
95% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.04 vs. SWTUY: 108.80 )
Ranked among companies with meaningful POCF only.
SWTUY' s 10-Year POCF Range
Min: 10.17  Med: 46.58 Max: 1930
Current: 108.8
10.17
1930
EV-to-EBIT 220.67
SWTUY's EV-to-EBIT is ranked lower than
97% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.19 vs. SWTUY: 220.67 )
Ranked among companies with meaningful EV-to-EBIT only.
SWTUY' s 10-Year EV-to-EBIT Range
Min: -5346.2  Med: -61.80 Max: 627.6
Current: 220.67
-5346.2
627.6
Current Ratio 2.58
SWTUY's Current Ratio is ranked lower than
52% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. SWTUY: 2.58 )
Ranked among companies with meaningful Current Ratio only.
SWTUY' s 10-Year Current Ratio Range
Min: 1.67  Med: 2.59 Max: 3.23
Current: 2.58
1.67
3.23
Quick Ratio 1.69
SWTUY's Quick Ratio is ranked lower than
61% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. SWTUY: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
SWTUY' s 10-Year Quick Ratio Range
Min: 0.66  Med: 1.49 Max: 1.85
Current: 1.69
0.66
1.85
Days Inventory 232.10
SWTUY's Days Inventory is ranked lower than
95% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. SWTUY: 232.10 )
Ranked among companies with meaningful Days Inventory only.
SWTUY' s 10-Year Days Inventory Range
Min: 75.88  Med: 274.15 Max: 566.43
Current: 232.1
75.88
566.43
Days Sales Outstanding 81.47
SWTUY's Days Sales Outstanding is ranked lower than
66% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. SWTUY: 81.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
SWTUY' s 10-Year Days Sales Outstanding Range
Min: 10.26  Med: 48.58 Max: 73.93
Current: 81.47
10.26
73.93

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 105.17
SWTUY's Price/Net Current Asset Value is ranked lower than
93% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.29 vs. SWTUY: 105.17 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SWTUY' s 10-Year Price/Net Current Asset Value Range
Min: 55.45  Med: 96.84 Max: 318.93
Current: 105.17
55.45
318.93
Price/Tangible Book 63.10
SWTUY's Price/Tangible Book is ranked lower than
100% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.08 vs. SWTUY: 63.10 )
Ranked among companies with meaningful Price/Tangible Book only.
SWTUY' s 10-Year Price/Tangible Book Range
Min: 7.32  Med: 72.62 Max: 2095
Current: 63.1
7.32
2095
Price/Projected FCF 7.25
SWTUY's Price/Projected FCF is ranked lower than
88% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. SWTUY: 7.25 )
Ranked among companies with meaningful Price/Projected FCF only.
SWTUY' s 10-Year Price/Projected FCF Range
Min: 4.45  Med: 8.63 Max: 12.98
Current: 7.25
4.45
12.98
Price/Median PS Value 1.20
SWTUY's Price/Median PS Value is ranked lower than
89% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. SWTUY: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
SWTUY' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 1.07 Max: 2.13
Current: 1.2
0.24
2.13
Price/Graham Number 21.03
SWTUY's Price/Graham Number is ranked lower than
100% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. SWTUY: 21.03 )
Ranked among companies with meaningful Price/Graham Number only.
SWTUY' s 10-Year Price/Graham Number Range
Min: 3.75  Med: 17.95 Max: 21.94
Current: 21.03
3.75
21.94
Earnings Yield (Greenblatt) (%) 0.50
SWTUY's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. SWTUY: 0.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SWTUY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 0.50 Max: 1.3
Current: 0.5
0.2
1.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:B6E.Germany, 0MTD.UK, SOBI.Sweden,
Swedish Orphan Biovitrum AB is a Sweden-based pharmaceutical company that markets specialist pharmaceuticals. Its research and development is focused on the development and production of biotechnology therapeutics within the areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care, and malabsorption. The company produces specialist pharmaceuticals that are intended to target small patient groups and are prescribed by medical specialists, as well as biopharmaceuticals, recombinant proteins produced using biotechnological processes similar to the body's own substances. The company develops its products either internally, or through partnerships with other pharmaceutical companies. Biovitrium promotes its proprietary products and prescription specialist products throughout Europe, North America, Australia, and New Zealand, in collaboration with Wyeth, Amgen, and other pharmaceutical and biotechnology comapanies. The company's pipeline includes the following products: Kepivance, a recombinant protein drug used to prevent inflammation and ulcers of the oral mucosa in patients suffering from hematologic cancer; Kiobrina, a recombinant human lipid-digesting enzyme (BSSL) for the purpose of improving fat absorption and increasing growth in premature infants; Exinalda, a biotechnologically produced recombinant human enzyme to improve treatment for patients suffering from fat malabsorption due to pancreatic insufficiency in diseases such as cystic fibrosis (CF); Factor IX Fc, a recombinant protein drug developed in combination with Biogen Idec for the treatment of hemophilia B, to name a few.
» More Articles for OTCPK:SWTUY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK